Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2010

Open Access 01-12-2010 | Hypothesis

Metabolic memory: a vascular perspective

Author: Thomas W Jax

Published in: Cardiovascular Diabetology | Issue 1/2010

Login to get access

Excerpt

Multiple and complex pathways promote the deleterious effects of hyperglycemia in diabetes, ultimately leading to micro- and macrovascular disease. Some of the known mechanisms in diabetic vascular disease may explain the initiation of the "metabolic memory", but fall short if long periods of time are involved. …
Appendix
Available only for authorised users
Literature
1.
Camici PG, Crea F: Coronary microvascular dysfunction. N Engl J Med. 2007, 356: 830-840. 10.1056/NEJMra061889.CrossRefPubMed
2.
3.
Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005, 353: 2643-2653. 10.1056/NEJMoa052187.CrossRefPubMed
4.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008, 359: 1577-1589. 10.1056/NEJMoa0806470.CrossRefPubMed
5.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998, 352: 837-853. 10.1016/S0140-6736(98)07019-6.
6.
Feskens EJ, Kromhout D: Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J Clin Epidemiol. 1992, 45: 1327-1334. 10.1016/0895-4356(92)90173-K.CrossRefPubMed
7.
Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009, 119: 351-357. 10.1161/CIRCULATIONAHA.108.191305.CrossRefPubMed
8.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008, 358: 2560-2572. 10.1056/NEJMicm066227.CrossRefPubMed
9.
Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008, 358: 2545-2559. 10.1056/NEJMoa0802743.CrossRefPubMed
10.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993, 329: 977-986. 10.1056/NEJM199309303291401.
11.
White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM: Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008, 126: 1707-1715. 10.1001/archopht.126.12.1707.CrossRefPubMed
12.
Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985, 34: 222-234. 10.2337/diabetes.34.3.222.CrossRefPubMed
13.
Ceriello A, Ihnat MA, Thorpe JE: Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?. J Clin Endocrinol Metab. 2009, 94: 410-415. 10.1210/jc.2008-1824.CrossRefPubMed
14.
Engerman RL, Kern TS: Progression of incipient diabetic retinopathy during good glycemic control. Diabetes. 1987, 36: 808-812. 10.2337/diabetes.36.7.808.CrossRefPubMed
15.
Roy S, Sala R, Cagliero E, Lorenzi M: Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci USA. 1990, 87: 404-408. 10.1073/pnas.87.1.404.PubMedCentralCrossRefPubMed
16.
17.
Szabo C: Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br J Pharmacol. 2009, 156: 713-727. 10.1111/j.1476-5381.2008.00086.x.PubMedCentralCrossRefPubMed
18.
Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, Calkin AC, Brownlee M, Cooper ME, El Osta A: Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009, 58: 1229-1236. 10.2337/db08-1666.PubMedCentralCrossRefPubMed
19.
El Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M: Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008, 205: 2409-2417. 10.1084/jem.20081188.PubMedCentralCrossRefPubMed
20.
Tonna S, El-Osta A, Cooper ME, Tikellis C: Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol. 2010, 6: 332-341. 10.1038/nrneph.2010.55.CrossRefPubMed
21.
Caplan BA, Schwartz CJ: Increased endothelial cell turnover in areas of in vivo Evans Blue uptake in the pig aorta. Atherosclerosis. 1973, 17: 401-417. 10.1016/0021-9150(73)90031-2.CrossRefPubMed
22.
Crosby JR, Kaminski WE, Schatteman G, Martin PJ, Raines EW, Seifert RA, Bowen-Pope DF: Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res. 2000, 87: 728-730.CrossRefPubMed
23.
Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA: Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest. 2000, 106: 571-578. 10.1172/JCI9087.PubMedCentralCrossRefPubMed
24.
Zampetaki A, Kirton JP, Xu Q: Vascular repair by endothelial progenitor cells. Cardiovasc Res. 2008, 78: 413-421. 10.1093/cvr/cvn081.CrossRefPubMed
25.
Dimmeler S, Zeiher AM: Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis?. J Mol Med. 2004, 82: 671-677. 10.1007/s00109-004-0580-x.CrossRefPubMed
26.
Urbich C, Dimmeler S: Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004, 95: 343-353. 10.1161/01.RES.0000137877.89448.78.CrossRefPubMed
27.
Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Tielsch JM, Klein BE, Hubbard LD: Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study. JAMA. 2002, 287: 1153-1159. 10.1001/jama.287.9.1153.PubMed
28.
McGeechan K, Liew G, Macaskill P, Irwig L, Klein R, Klein BE, Wang JJ, Mitchell P, Vingerling JR, Dejong PT, Witteman JC, Breteler MM, Shaw J, Zimmet P, Wong TY: Meta-analysis: retinal vessel caliber and risk for coronary heart disease. Ann Intern Med. 2009, 151: 404-413.PubMedCentralCrossRefPubMed
29.
Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY: Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2007, 30: 1742-1746. 10.2337/dc07-0264.CrossRefPubMed
30.
McGeechan K, Liew G, Macaskill P, Irwig L, Klein R, Klein BE, Wang JJ, Mitchell P, Vingerling JR, de Jong PT, Witteman JC, Breteler MM, Shaw J, Zimmet P, Wong TY: Prediction of incident stroke events based on retinal vessel caliber: a systematic review and individual-participant meta-analysis. Am J Epidemiol. 2009, 170: 1323-1332. 10.1093/aje/kwp306.PubMedCentralCrossRefPubMed
31.
Witt N, Wong TY, Hughes AD, Chaturvedi N, Klein BE, Evans R, McNamara M, Thom SA, Klein R: Abnormalities of retinal microvascular structure and risk of mortality from ischemic heart disease and stroke. Hypertension. 2006, 47: 975-981. 10.1161/01.HYP.0000216717.72048.6c.CrossRefPubMed
32.
Mitchell P, Wang JJ, Wong TY, Smith W, Klein R, Leeder SR: Retinal microvascular signs and risk of stroke and stroke mortality. Neurology. 2005, 65: 1005-1009. 10.1212/01.wnl.0000179177.15900.ca.CrossRefPubMed
33.
Lekakis JP, Papamichael CM, Vemmos CN, Voutsas AA, Stamatelopoulos SF, Moulopoulos SD: Peripheral vascular endothelial dysfunction in patients with angina pectoris and normal coronary arteriograms. J Am Coll Cardiol. 1998, 31: 541-546. 10.1016/S0735-1097(97)00542-1.CrossRefPubMed
34.
Sax FL, Cannon RO, Hanson C, Epstein SE: Impaired forearm vasodilator reserve in patients with microvascular angina. Evidence of a generalized disorder of vascular function?. N Engl J Med. 1987, 317: 1366-1370. 10.1056/NEJM198711263172202.CrossRefPubMed
35.
Tso MO, Jampol LM: Pathophysiology of hypertensive retinopathy. Ophthalmology. 1982, 89: 1132-1145.CrossRefPubMed
36.
Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD, Cleutjens JP, van den Akker LH, Corvol P, Wouters BG, Daemen MJ, Bijnens AP: Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol. 2008, 51: 1258-1265. 10.1016/j.jacc.2007.12.025.CrossRefPubMed
37.
Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414: 813-820. 10.1038/414813a.CrossRefPubMed
38.
Gross ML, Heiss N, Weckbach M, Hansen A, El Shakmak A, Szabo A, Munter K, Ritz E, Amann K: ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes. Diabetologia. 2004, 47: 316-324. 10.1007/s00125-003-1309-z.CrossRefPubMed
39.
Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984, 74: 1143-1155. 10.1172/JCI111523.PubMedCentralCrossRefPubMed
40.
Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H: Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 2000, 101: 899-907.CrossRefPubMed
41.
42.
Aird WC: Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res. 2007, 100: 174-190. 10.1161/01.RES.0000255690.03436.ae.CrossRefPubMed
43.
Aird WC: Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007, 100: 158-173. 10.1161/01.RES.0000255691.76142.4a.CrossRefPubMed
44.
Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS, Wang Z, Rockson SG, van de RM, Botstein D, Brown PO: Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci USA. 2003, 100: 10623-10628. 10.1073/pnas.1434429100.PubMedCentralCrossRefPubMed
45.
Kelm M: [Interaction of the coronary macro- and microcirculation]. Z Kardiol. 2001, 90: 946-952. 10.1007/s003920170065.CrossRefPubMed
46.
Wiernsperger NF: In defense of microvascular constriction in diabetes. Clin Hemorheol Microcirc. 2001, 25: 55-62.PubMed
47.
Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002, 288: 2579-2588. 10.1001/jama.288.20.2579.CrossRefPubMed
48.
49.
Marcus ML, Chilian WM, Kanatsuka H, Dellsperger KC, Eastham CL, Lamping KG: Understanding the coronary circulation through studies at the microvascular level. Circulation. 1990, 82: 1-7.CrossRefPubMed
50.
Tiefenbacher CP, Chilian WM: Heterogeneity of coronary vasomotion. Basic Res Cardiol. 1998, 93: 446-454. 10.1007/s003950050114.CrossRefPubMed
51.
Deussen A, Schrader J: Cardiac adenosine production is linked to myocardial pO2. J Mol Cell Cardiol. 1991, 23: 495-504. 10.1016/0022-2828(91)90173-J.CrossRefPubMed
52.
Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess O, Indolfi C, Rimoldi O: alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation. 2000, 101: 689-694.CrossRefPubMed
53.
Gould KL: Pressure-flow characteristics of coronary stenoses in unsedated dogs at rest and during coronary vasodilation. Circ Res. 1978, 43: 242-253.CrossRefPubMed
54.
Hess OM, Buchi M, Kirkeeide R, Niederer P, Anliker M, Gould KL, Krayenbuhl HP: Potential role of coronary vasoconstriction in ischaemic heart disease: effect of exercise. Eur Heart J. 1990, 11 (Suppl B): 58-64.CrossRefPubMed
55.
Strauer BE: The significance of coronary reserve in clinical heart disease. J Am Coll Cardiol. 1990, 15: 775-783. 10.1016/0735-1097(90)90273-R.CrossRefPubMed
56.
Zeiher AM, Drexler H, Wollschlager H, Just H: Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation. 1991, 84: 1984-1992.CrossRefPubMed
57.
Antony I, Lerebours G, Nitenberg A: Loss of flow-dependent coronary artery dilatation in patients with hypertension. Circulation. 1995, 91: 1624-1628.CrossRefPubMed
58.
Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH: Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res. 1994, 74: 349-353.CrossRefPubMed
59.
Hayden MR, Tyagi SC: Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol. 2004, 3: 1-10.1186/1475-2840-3-1.PubMedCentralCrossRefPubMed
60.
Rizzoni D, Muiesan ML, Porteri E, De CC, Boari GE, Salvetti M, Paini A, Rosei EA: Vascular remodeling, macro- and microvessels: therapeutic implications. Blood Press. 2009, 18: 242-246.CrossRefPubMed
61.
Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A, Girelli A, Rodella L, Bianchi R, Sleiman I, Rosei EA: Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation. 2001, 103: 1238-1244.CrossRefPubMed
62.
Rizzoni D, Rosei EA: Small artery remodeling in diabetes mellitus. Nutr Metab Cardiovasc Dis. 2009, 19: 587-592. 10.1016/j.numecd.2009.03.011.CrossRefPubMed
63.
Schofield I, Malik R, Izzard A, Austin C, Heagerty A: Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation. 2002, 106: 3037-3043. 10.1161/01.CIR.0000041432.80615.A5.CrossRefPubMed
Metadata
Title
Metabolic memory: a vascular perspective
Author
Thomas W Jax
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2010
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-9-51

Other articles of this Issue 1/2010

Cardiovascular Diabetology 1/2010 Go to the issue

Original investigation

Fibrinogen and associated risk factors in a high-risk population: urban indigenous australians, the druid Study

Original investigation

log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males

Commentary

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study

Original investigation

Insulin resistance in Chinese patients with type 2 diabetes is associated with C-reactive protein independent of abdominal obesity

Original investigation

Oxidant-NO dependent gene regulation in dogs with type I diabetes: impact on cardiac function and metabolism

Original investigation

The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits